First Case of Skin and Soft Tissue Infection Caused by Mycoplasma hominis in a Pediatric Immunocompromised Patient

• Published in: Annals of laboratory medicine Vol. 37; no. 4; pp. 346 - 348
• Main Authors: Cho, Hanwool, Park, Kang Gyun, Han, Seong Beom, Chung, Nack Gyun, Park, Yeon Joon
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Society for Laboratory Medicine 01.07.2017; 대한진단검사의학회
• Subjects: Adolescent; Anti-Bacterial Agents - therapeutic use; Dibekacin - analogs & derivatives; Dibekacin - therapeutic use; DNA, Bacterial - genetics; DNA, Bacterial - metabolism; Female; Graft vs Host Disease - etiology; Humans; Immunocompromised Host; Letter to the Editor; Mycoplasma hominis - chemistry; Mycoplasma hominis - genetics; Mycoplasma hominis - isolation & purification; Mycoplasma Infections - diagnosis; Mycoplasma Infections - drug therapy; Mycoplasma Infections - microbiology; Polymerase Chain Reaction; Soft Tissue Infections - diagnosis; Soft Tissue Infections - drug therapy; Soft Tissue Infections - microbiology; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tigecycline - therapeutic use; Transplantation, Homologous - adverse effects; 병리학
• ISSN: 2234-3806; 2234-3814
• DOI: 10.3343/alm.2017.37.4.346

Dear Editor, Mycoplasma hominis is a part of the urogenital commensal flora, with higher bacterial loads in women compared with men. Thus, infections of M. hominis are usually associated with endocervicitis and pelvic inflammatory diseases. Although rare, M. hominis can also cause various extra-urogenital infections, such as skin and soft tissue infections (SSTIs) [1, 2], central nervous system (CNS) infection, mediastinitis, and disseminated infection [3-6]. Because M. hominis lacks a cell wall and shows resistance to cell wall-acting antibiotics, including carbapenem and glycopeptides, it is important to accurately identify this bacterium and initiate appropriate treatment in the case of infection. Clindamycin shows the highest in vitro activity against M. hominis, followed by fluoroquinolones [4]. KCI Citation Count: 2